Gukjeon Yakpum Signs Commercialization Agreement for Photoreactive Cancer Treatment and Diagnostic Technology with Hallim Pharmaceutical and Dr. I&V

Gukjeon Pharm announced on the 20th that it has signed an agreement with Hallim Pharmaceutical and Dr. I&B for the "Successful Commercialization of Photodynamic Therapy (PDT) Anticancer Treatment and Diagnostic Technology."

This project aims to develop ‘PP-100,’ a patented photodynamic new drug substance developed by Dr. I&B, into a photodynamic agent new drug (PhotoMed). Gukjeon Pharm will be responsible for developing the GMP mass production process of this new drug substance and producing the active pharmaceutical ingredient (API).

This agreement is significant as Gukjeon Pharm, which had previously focused on APIs for chronic diseases, has expanded its anticancer treatment lineup by developing anticancer tumor diagnostics following its joint investment with SN Bioscience in nano anticancer therapeutics.

A representative from Gukjeon Pharm stated, “Based on the marketing and sales capabilities accumulated through the manufacturing and sales of APIs, we plan to challenge the anticancer treatment market and expand our portfolio as a chemical total solution company.”

Meanwhile, Gukjeon Pharm established a joint venture, KS Biologics, with SN Bioscience, a developer of nano anticancer injectable drugs, and is currently building an anticancer drug factory in Eumseong, Chungbuk, to conduct nano anticancer drug and CMO businesses targeting the global market.